Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy work in different ways to stop cancer cells from dividing so they stop growing
or die. Combining rituximab with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy works in treating patients with newly diagnosed Waldenstrom's macroglobulinemia.